AIDS 2026, the 26th International AIDS Conference, taking place in Rio de Janeiro, Brazil, and virtually, comes at a crucial time for the HIV response. In the face of an unprecedented funding crisis and major cutbacks to HIV programs, the world’s largest conference on HIV and AIDS will bring together people living with HIV, researchers, policy makers, healthcare professionals, funders, media and communities—to rethink, rebuild and rise.
Posters will be displayed all day; presenters will be by their poster from 12:00 to 13:00
Results from a US Pilot Evaluation of Journeys, a Status-neutral Group Program to Address Multiple Stigmas and Support Mental Health, HIV Wellness, and Shared Resilience (THPED319) (Abstract)
DeMarc A. Hickson
Bridging the Evidence-to-action Gap: Leveraging AI and centralised data hub to strengthen HIV prevention programming in sub-Saharan Africa (THPEE587) (Abstract)
Anticipating Implementation Challenges to Lenacapavir Introduction in Uganda: A pre-mortem analysis (THPEF634) (Abstract)
Results of a Randomized, Double-blind, Phase 1b Study to Evaluate the Pharmacokinetics, Safety, and Bleeding Associated with Two 90-day Multipurpose Dapivirine-levonorgestrel Vaginal Rings for HIV and Pregnancy Prevention (OAC2804) (Abstract)
From Choice to Impact: Long-acting and multipurpose HIV prevention technologies (Abstract)
Hosted by IPM South Africa NPC, an affiliate of the Population Council
Choice is central to effective HIV prevention. As the prevention landscape evolves, sustaining a range of user-centered options is essential to meeting the diverse needs of people at risk of HIV, particularly women and adolescent girls. This satellite session explores the future of HIV prevention choice through multipurpose prevention technologies (MPTs) and longer-acting delivery systems. Focusing on innovations such as emerging three-month rings and dapivirine–levonorgestrel vaginal ring, the session examines how MPTs can address HIV prevention alongside contraceptive needs, reduce user burden, and support adherence. Speakers will discuss scientific advances, implementation considerations, and access pathways, alongside perspectives from researchers, implementers, governments, advocates, and communities. By convening diverse stakeholders, the session highlights the role of long-acting, user-controlled technologies in strengthening prevention choice and equity in the HIV response.
